Advaxis Inc :A loss of 4 cents per share anticipated for third quarter

Ayala Pharmaceuticals

09/09/2021 03:51

9 September 202102:51 a.m. All figures in US dollars. 
Advaxis Inc is expected to show an increase in its third quarter
earnings to -4 cents​ per share according to the single analyst
providing an estimate for the quarter. ​  
 
RECOMMENDATIONS 
* The single recommendation for the company is "Buy".  
* The average consensus recommendation for the biotechnology &
medical research peer group is also "Buy". 
 
FORECAST CHANGES
* One analyst is currently providing Refinitiv with estimates. 
* In the last week there have been no earnings estimate
revisions by analysts covering the company. There were no
changes to the number of estimates.
* In the last four weeks the earnings per share estimate   is
unchanged  from -4 cents.  .  There has been no changes to the
number of estimates.
* The StarMine predicted earnings surprise is currently
unavailable. Predicted revenue surprise is not available.
* The price target from the one analyst providing an estimate is
$2.25.
 
YEAR OVER YEAR
* The company is expecting to report no change from the  $0
revenue reported in the same quarter last year. 
* The current quarter consensus estimate of  -4 cents per
share   implies a gain of 55.56 percent from the same quarter
last year when the company reported -9 cents per share.
* Previous quarterly performance (using preferred earnings
measure)
 QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2021      0.26           0.29           Beat
 Mar. 31 2021      0.27           0.29           Beat
 Dec. 31  2020     0.31           0.35           Beat
 Sep. 30 2020      0.32           0.41           Beat
 
This summary was machine generated from Refinitiv data September
9 at 02:51 a.m